Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ -1.37MWorking Capital
VS
Market
Sector
Industry
History
$ 2.31Close
$ 1.11 - $ 4.65 52-Week Range
Ticker Information
Ticker
SABSCompany Name
SAB BIOTHERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQSAB BIOTHERAPEUTICS INC - Working Capital Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
SABS - Working Capital Historical data
| Date | Current Assets | Current Liabilities | Working Capital |
|---|---|---|---|
| 6/30/2025 | $ 9.31M | $ 10.68M | $ -1.37M |
| 3/31/2025 | $ 16.3M | $ 9.65M | $ 6.64M |
| 12/31/2024 | $ 23.79M | $ 7.98M | $ 15.81M |
| 9/30/2024 | $ 32.54M | $ 8.82M | $ 23.72M |
| 6/30/2024 | $ 39.58M | $ 7.55M | $ 32.03M |
| 3/31/2024 | $ 46.95M | $ 8.3M | $ 38.65M |
| 12/31/2023 | $ 58.91M | $ 10.81M | $ 48.09M |
| 9/30/2023 | $ 3.13M | $ 9.21M | $ -6.08M |
| 6/30/2023 | $ 9.01M | $ 11.01M | $ -2M |
| 3/31/2023 | $ 15.03M | $ 13.67M | $ 1.37M |
Key Performance Insights, Last 5 Years
- SAB BIOTHERAPEUTICS INC's latest trailing twelve months (TTM) Working Capital stands at $ 0.
- Over the past 5 years, SAB BIOTHERAPEUTICS INC's average Working Capital has been $ 14.78M.
- The median Working Capital for SAB BIOTHERAPEUTICS INC during this period was $ 11.61M
- SAB BIOTHERAPEUTICS INC reached its highest Working Capital over the past 5 years at $ 48.09M.
- The lowest Working Capital recorded by SAB BIOTHERAPEUTICS INC in the same timeframe $ -6.08M
SAB BIOTHERAPEUTICS INC's Working Capital vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
Working Capital Benchmarks
Similar metrics to Working Capital:
- Current Ratio - [Calculation] The current ratio is a liquidity indicator that describes the company’s ability to pay short-term obligations due within one year. Calculated by dividing current assets [AssetsC] by current liabilities [LiabilitiesC].
- Quick Ratio - [Calculation] The quick ratio is a liquidity indicator that describes the company’s ability to pay short-term obligations without the need to sell its inventory or receive additional financing. Calculated by dividing current assets [AssetsC] minus [Inventory] by current liabilities [LiabilitiesC].
- Current Liabilities - [Balance Sheet] The current (short-term) portion of [Liabilities] includes obligations that are due to be paid to creditors within one year, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
- Total Liabilities - [Balance Sheet] Total liabilities are the sum of all possible claims against the company. Common examples are [Debt], [Payables], deferred revenues, issued bonds, warranties, and tax liabilities.
- Non-Current Liabilities - [Balance Sheet] The non-current (long-term) portion of [Liabilities] includes obligations that are due to be paid to creditors more than year in the future, reported if the company operates a classified balance sheet that segments current and non-current [Liabilities]
Definition of Working Capital
[Calculation] The working capital represents the capital used in day-to-day operations. It is the difference between a company’s short-term assets [AssetsC] and current liabilities [LiabilitiesC].AssetsC - LiabilitesC
(=) Working Capital Working Capital for SAB BIOTHERAPEUTICS INC is calculated as follows: AssetsC [ $ 0 ] - LiabilitesC [ $ 55.56K ]
(=) Working Capital [ $ 0 ] SABS - Working Capital, Last 5 years
$ -6.08M
Minimum
Sep 30, 2023
$ 48.09M
Maximum
Dec 31, 2023
$ 14.78M
Average
$ 11.61M
Median
Working Capital Benchmark AnalysisMarket
The chart above depicts the distribution of Working Capital for companies in the Total Stock Market. The average Working Capital of the companies is $ 96.44M with a standard deviation of $ 173.86M.
The following table provides additional summary stats:
Working Capital in the Market:
| filtered constituents | 2.78K |
|---|---|
| min | $ -465.2M |
| max | $ 607.04M |
| average | $ 96.44M |
| median | $ 32.21M |
| std | $ 173.86M |